摘要
目的:探讨晚期上皮性卵巢癌复发患者采用白蛋白结合型紫杉醇联合卡铂治疗的临床疗效及预后。方法:选取2020年1月-2024年4月在本院治疗的晚期上皮性卵巢癌复发患者88例,根据最终选取的治疗方案分为观察组(n=46)和对照组(n=42),观察组给予白蛋白结合型紫杉醇联合卡铂治疗,对照组给予常规紫杉醇联合卡铂治疗,观察两组临床疗效、预后等。结果:观察组疾病控制率(80.4%)高于对照组(54.8%),治疗后糖类抗原125(CA125)(143.30±39.39U/ml)低于对照组(190.02±40.05 U/ml),治疗后生命质量问卷-卵巢癌28功能状态评分(75.23±9.95分)低于对照组(81.21±9.61分),Ⅲ~Ⅳ中性粒细胞减少、Ⅲ~Ⅳ血小板降低发生率(均为0)低于对照组(14.3%、19.1%),中位总生存期(42个月)长于对照组(33个月),完全缓解、部分缓解患者治疗前CA125(440.30±70.50U/ml)低于稳定、进展患者(513.89±72.22 U/ml)(均P<0.05)。结论:晚期上皮性卵巢癌复发患者采用白蛋白结合型紫杉醇联合卡铂治疗临床效果提高,生存情况有所改善,其疗效可能与治疗前CA125水平有关。
Objective:To explore the efficacy and prognosis of albumin bound paclitaxel combined with carboplatin for treating patients with recurrent advanced epithelial ovarian cancer(RAEOC).Methods:88 patients with RAEOC treated in the hospital were selected and were divide into observation group(n=46)and control group(n=42)based on their final treatment plan from January 2020 to April 2024.The patients in the observation group received the treatment of albumin bound paclitaxel combined with carboplatin,while the patients in the control group received the treatment of conventional paclitaxel combined with carboplatin.The clinical efficacy and prognosis of the patients in the two groups were observed.Results:The disease control rate(80.4%)of the patients in the observation group was significantly higher than that(54.8%)of the patients in the control group,and the carbohydrate antigen 125(CA125)level(143.30±39.39U/ml)of the patients in the observation group after treatment was significantly lower than that(190.02±40.05 U/ml)of the patients in the control group.After treatment,the score of questionnaire ovarian cancer 28 functional status on the quality of life(75.23±9.95 points)of the patients in the observation group was significantly lower than that(81.21±9.61 points)of the patients in the control group.The incidences ofⅢ-Ⅳneutropenia decrease(0)andⅢ-Ⅳthrombocytopenia decrease(0)of the patients in the observation group were significantly lower than those(14.3%and 19.1%)of the patients in the control group.The median overall survival time(42 months)of the patients in the observation group was significantly longer than that(33 months)of the patients in the control group.The CA125 level(440.30±70.50U/ml)of the patients with complete remission and partial remission before treatment was significantly lower than that(513.89±72.22U/ml)of the patients with stable and progressive disease(all P<0.05).Conclusion:Albumin-bound paclitaxel combined with carboplatin for treating the patients with RAEOC can improve their clinical efficacy and survival,which may be correlation with the level of CA125of the patients before treatment.
作者
强恒华
苏磊
潘刚
邵茜茜
QIANG Henghua;SU Lei;PAN Gang;SHAO Qianqian(Suixi County Hospital,Huaibei,Anhui Province,235100;Huaibei Miners General Hospital,Huaibei,Anhui Province)
出处
《中国计划生育学杂志》
2025年第2期269-273,279,共6页
Chinese Journal of Family Planning
关键词
晚期复发上皮性卵巢癌
白蛋白结合型紫杉醇
卡铂
糖类抗原125
临床疗效
预后
Recurrent advanced epithelial ovarian cancer
Albumin bound paclitaxel
Carboplatin
Carbohydrate anti-gen 125
Clinical efficacy
Prognosis
